BRINAVESS® (vernakalant hydrochloride, IV) is a relatively atrial selective antiarrhythmic agent that prolongs atrial refractoriness (or insensitivity to further immediate stimulation) and rate-dependently slows impulse conduction. The relative selectivity of BRINAVESS on atrial versus ventricular refractoriness is postulated to result from the unique condition of the fibrillating atria and blocking currents that are specifically expressed in the atria, but not those that impact ventricular conduction. The targeted effects of BRINAVESS on atrial tissue coupled with blocking of the late sodium current suggests that BRINAVESS has a low proarrhythmic potential.
The current BRINAVESS Summary of Product Characteristics, in all EU languages, can be found here
The Pre-Infusion checklist for BRINAVESS for EU countries can be requested at email@example.com